13F Holdings
中文EN

CMPX Compass Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1738021 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-31.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-49.0%
ROA-42.6%
ROIC (approx.)-56.2%
Asset turnover—

Leverage & solvency

Liabilities / assets18.3%
Debt / equity0.00x
Current ratio6.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$850,000$0——
R&D expense$55.97M$42.34M$38.12M$30.00M$20.34M
SG&A expense$16.87M$15.13M$12.24M$11.66M$10.93M
Operating income-$72.84M-$56.62M-$50.36M-$41.66M-$81.88M
Interest expense———$0$370,000
Pretax income——-$42.49M-$39.23M-$82.18M
Income tax$0$0$0$0$0
Net income-$66.49M-$49.38M-$42.49M-$39.23M-$82.18M
EBITDA-$72.56M-$56.04M-$49.66M-$40.87M-$81.32M
EPS (basic)-0.42-0.36-0.33-0.37-1.31
EPS (diluted)————-1.31
Weighted avg. shares (diluted)—137.40M——62.87M
Balance sheet
Cash & equivalents$30.64M$43.48M$24.23M$34.95M$144.51M
Short-term investments$178.26M$83.24M$128.23M$151.66M$0
Current assets$209.82M$132.75M$153.88M$194.79M$147.10M
PP&E, net$102,000$353,000$898,000$1.57M$2.24M
Total assets$219.59M$140.40M$156.88M$199.65M$153.76M
Current liabilities$13.97M$8.87M$7.80M$16.17M$10.63M
Short-term debt————$0
Long-term debt————$0
Total debt————$0
Total liabilities$22.80M$15.17M$8.34M$18.01M$13.68M
Shareholders' equity$196.79M$125.23M$148.54M$181.64M$140.08M
Net debt————-$144.51M
Shares outstanding178.32M137.82M127.67M126.30M100.83M
Cash flow statement
Operating cash flow-$49.14M-$44.85M-$40.62M-$34.12M-$19.67M
Capital expenditure$25,000$44,000$30,000$212,000$1.57M
Free cash flow-$49.17M-$44.90M-$40.65M-$34.34M-$21.23M
Investing cash flow-$93.31M$46.77M$26.96M-$151.20M-$1.77M
Financing cash flow$129.61M$17.34M$2.94M$75.76M$118.61M
Depreciation & amortization$276,000$589,000$699,000$782,000$566,000
Stock-based compensation$8.37M$8.56M$6.12M$5.33M$4.03M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.